Google Alert - hepatitis c

[Guest guest]

News

6 new results for hepatitis c

New Hepatitis C Drugs Approaching Finish LineRTT News(RTTNews) - Hepatitis C, an infection of the liver, is caused by the deadly hepatitis C virus. This contagious liver disease can be either acute or chronic. Currently there is no vaccine to prevent hepatitis C. But there are approved anti-viral ...See all stories on this topic »

Reasons for compliance or noncompliance with advice to test for hepatitis C ...7thSpace Interactive (press release)Hepatitis C virus (HCV) is mainly transmitted by exposure to infected blood, and can lead to liver cirrhosis and liver cancer. Since the onset of HCV and the development of liver cirrhosis usually are asymptomatic, many

HCV-infected individuals are ...See all stories on this topic »

Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Reports FDA Meeting Request ...InvestorIdeas.com (press release)Aethlon management will present FDA officials with new clinical data that supports the safety of the Hemopurifier® and demonstrates the capability of the medical device to reduce viral load in individuals infected with the hepatitis C virus (HCV). ...See all stories on this topic »

Merck Sharpe and Dohme launches new hepatitis education campaignZenopaMerck Sharpe and Dohme has announced the launch of a new corporate initiative that is designed to raise awareness of the issues affecting patients with hepatitis C. The Hope Against Hepatitis C scheme will incorporate a number of educational programmes ...See all stories on this topic »

New Study Recommends Screening To Prevent Liver DiseasesTopNews United StatesA new study has claimed that screening people born between 1946 and 1970 for Hepatitis C would be helpful in reducing the number of people suffering from liver disease. The study was funded by Vertex Pharmaceuticals which is developing a new Hepatitis ...See all stories on this topic »

TopNews United States

Ligand Pharmaceuticals Reports First Quarter Results4-traders (press release)With several major near-term catalysts anticipated, including pivotal data from two Phase III trials with Promacta® in patients with hepatitis C, 2011 is shaping up to be a momentous year for Ligand." Total revenues from continuing operations for the ...See all stories on this topic »